Phobia, Social: Clinical Trials

16 trials for Phobia, Social, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 terminated, 2 withdrawn, 1 unknown. 16 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 11, Terminated 2, Withdrawn 2, Unknown 1
Phase 26Completed 6

Follow Phobia, Social: new trials by email Literature Review of Phobia, Social trials Research Report on Phobia, Social

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
Propranolol, Prazosin - Post-traumatic Stress Disorder (PTSD)
Phase 1TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.342022-09-072024-01-23
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Low dose RLS103, High dose RLS103, placebo inhaled dry powder - Social Anxiety Disorder
Phase 1WithdrawnReceptor Life Sciences2022-05-182024-04-02
Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers
Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages, Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages, Phase 2: re-engagement text messages - Social Anxiety Disorder, Tobacco Use Disorder
Phase 1WithdrawnFred Hutchinson Cancer Center2022-04-152021-12-08
Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers
Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg - Major Depressive Disorder, Obsessive-Compulsive Disorder
Phase 1CompletedBeijing Tongren Hospital532018-03-292018-12-19
The Modular Protocol for Mental Health (MPMH)
The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder
Phase 1 / Phase 2CompletedMedical Research Council Cognition and Brain Sciences Unit432017-07-182020-09-29
Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training
Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy - Phobias, Claustrophobia
Phase 1 / Phase 2CompletedUniversity of Texas at Austin1122015-08-012022-12-28
Brief Behavioral Treatment for Anxiety in Young Children
Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia
Phase 1 / Phase 2CompletedUniversity of South Florida582014-01-012016-10-06
Generalization of Extinction Learning
Scopolamine, intranasal placebo - Social Anxiety Disorder
Phase 1CompletedUniversity of California, Los Angeles602013-08-012019-10-07
Bringing What Works to Youth in Corrections: A Trauma Intervention
Trauma-Focused Cognitive Behavioral Therapy - Post-Traumatic Stress Disorder
Phase 1 / Phase 2CompletedUniversity of Texas at Austin572012-11-012016-03-17
Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder
Oxytocin, Placebo - Social Anxiety Disorder
Phase 1 / Phase 2CompletedStefan G. Hofmann602012-07-012018-02-13
Treatment Study for Rural Latino Youth With Anxiety
Therapist-Assisted by Telephone, Self-Help - Anxiety Disorders, Separation Anxiety Disorder
Phase 1 / Phase 2CompletedUniversity of California, San Diego432011-11-012019-08-15
Cipralex® for Anxiety Disorders in Adolescents
Cipralex® - Anxiety Disorder
Phase 1UnknownUniversity of Ottawa302008-03-012011-02-11
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
GW876008, COC - Social Phobia
Phase 1TerminatedGlaxoSmithKline42007-06-082017-08-04
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia
Phase 1CompletedGlaxoSmithKline352007-03-272017-08-04
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
Placebo treatment during 8 weeks, Paroxetine treatment during 8 weeks - Social Phobia
Phase 1CompletedGlaxoSmithKline562007-01-222017-07-18
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
GW679769 - Social Anxiety Disorder
Phase 1CompletedGlaxoSmithKline572006-01-012008-10-16

Narrower conditions

Generalized Anxiety Disorder (7)  ·  Panic Disorder (5)  ·  Anxiety Disorders (4)  ·  Depressive Disorder, Major (4)  ·  Obsessive-Compulsive Disorder (4)  ·  Anxiety, Separation (3)  ·  Stress Disorders, Post-Traumatic (3)  ·  Phobia, Specific (2)  ·  Agoraphobia (1)  ·  Claustrophobia (1)  ·  Depression (1)  ·  Dysthymic Disorder (1)  ·  Fractures, Stress (1)  ·  Glossophobia (1)

Broader conditions

Mental Disorders (15)  ·  Phobic Disorders (15)  ·  Anxiety Disorders (12)  ·  Depressive Disorder (4)  ·  Mood Disorders (4)  ·  Neurodevelopmental Disorders (3)  ·  Stress Disorders, Traumatic (3)  ·  Trauma and Stressor Related Disorders (3)  ·  Behavior (1)  ·  Behavioral Symptoms (1)  ·  Chemically-Induced Disorders (1)  ·  Communication Disorders (1)  ·  Fractures, Bone (1)  ·  Language Disorders (1)  ·  Nervous System Diseases (1)

Interventions

GW 876008 (2)  ·  Alprazolam (1)  ·  Dexetimide (1)  ·  Implosive Therapy (1)  ·  Low-Level Light Therapy (1)  ·  Mental Health (1)  ·  NBI 77860 (1)  ·  Oxytocin (1)  ·  Paroxetine (1)  ·  Prazosin (1)  ·  Propranolol (1)  ·  Scopolamine (1)  ·  Therapeutics (1)  ·  casopitant (1)

Sponsors

GlaxoSmithKline (4)  ·  University of Texas at Austin (2)  ·  Beijing Tongren Hospital (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Medical Research Council Cognition and Brain Sciences Unit (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  Receptor Life Sciences (1)  ·  Stefan G. Hofmann (1)  ·  University of California, Los Angeles (1)  ·  University of California, San Diego (1)  ·  University of Ottawa (1)  ·  University of South Florida (1)

Countries

United States (10)  ·  Spain (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  China (1)

Top investigators

Denise A Chavira, PhD (1)  ·  Martine Flament, MD (1)  ·  Michael Fanselow, Ph.D. (1)  ·  Michael J. Telch, Ph.D. (1)  ·  Michelle G. Craske, Ph.D. (1)  ·  Molly M Lopez, Ph.D. (1)  ·  Noreen Watson (1)  ·  Tim Dalgleish, PhD (1)  ·  Xiuli Zhao, PhD (1)

Results publications

PMID 28559206, PMID 29792485, PMID 30082367, PMID 31174846, PMID 34284836

NIH funding

K23DA048181 (1), R34MH090149 (1), R34MH095210 (1)